Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 US Food and Drug Administration approval overview in metastatic breast cancer.

Literature DB >> 22430273

US Food and Drug Administration approval overview in metastatic breast cancer.

Patricia Cortazar¹, Robert Justice, John Johnson, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2012 PMID： 22430273 PMCID： PMC3383116 DOI： 10.1200/JCO.2011.39.2613

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

× No keyword cloud information.

23 in total

1. Detecting an overall survival benefit that is derived from progression-free survival.

Authors: Kristine R Broglio; Donald A Berry
Journal: J Natl Cancer Inst Date: 2009-11-09 Impact factor: 13.506

Review 2. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

Authors: Edward L Korn; Boris Freidlin; Jeffrey S Abrams
Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544

3. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors: Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal: N Engl J Med Date: 2006-12-28 Impact factor: 91.245

4. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Authors: William J Gradishar; Sergei Tjulandin; Neville Davidson; Heather Shaw; Neil Desai; Paul Bhar; Michael Hawkins; Joyce O'Shaughnessy
Journal: J Clin Oncol Date: 2005-09-19 Impact factor: 44.544

5. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

Authors: J L Blum; S E Jones; A U Buzdar; P M LoRusso; I Kuter; C Vogel; B Osterwalder; H U Burger; C S Brown; T Griffin
Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544

6. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.

Authors: J M Nabholtz; H J Senn; W R Bezwoda; D Melnychuk; L Deschênes; J Douma; T A Vandenberg; B Rapoport; R Rosso; V Trillet-Lenoir; J Drbal; A Molino; J W Nortier; D J Richel; T Nagykalnai; P Siedlecki; N Wilking; J Y Genot; P S Hupperets; F Pannuti; D Skarlos; E M Tomiak; M Murawsky; M Alakl; M Aapro
Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544

Review 7. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.

Authors: Everardo D Saad; Artur Katz; Marc Buyse
Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544

8. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors: Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal: N Engl J Med Date: 2007-12-27 Impact factor: 91.245

9. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Authors: Eva S Thomas; Henry L Gomez; Rubi K Li; Hyun-Cheol Chung; Luis E Fein; Valorie F Chan; Jacek Jassem; Xavier B Pivot; Judith V Klimovsky; Fernando Hurtado de Mendoza; Binghe Xu; Mario Campone; Guillermo L Lerzo; Ronald A Peck; Pralay Mukhopadhyay; Linda T Vahdat; Henri H Roché
Journal: J Clin Oncol Date: 2007-10-29 Impact factor: 44.544

10. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

Authors:
Journal: Health Qual Life Outcomes Date: 2006-10-11 Impact factor: 3.186

20 in total

10. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.

Authors: Joyce O'Shaughnessy; William J Gradishar; Paul Bhar; Jose Iglesias
Journal: Breast Cancer Res Treat Date: 2013-04-06 Impact factor: 4.872

US Food and Drug Administration approval overview in metastatic breast cancer.

1. Detecting an overall survival benefit that is derived from progression-free survival.

Review 2. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

3. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

4. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

5. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

6. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.

Review 7. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.

8. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

9. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

10. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

1. Frontiers in Intravital Multiphoton Microscopy of Cancer.

Review 2. Nanoparticle-mediated targeted drug delivery for breast cancer treatment.

3. Doxorubicin obliterates mouse ovarian reserve through both primordial follicle atresia and overactivation.

Review 4. Mechanisms of cancer cell death induction by paclitaxel: an updated review.

5. Triple negative breast cancer: approved treatment options and their mechanisms of action.

Review 6. Clinically Applicable Inhibitors Impacting Genome Stability.

7. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.

Review 8. Breast cancer: Muscarinic receptors as new targets for tumor therapy.

9. Taxanes for the treatment of metastatic breast cancer.

10. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis.